Get started
Author

Virginia Bove

Observed name: V. Bove
ORCID: 0000-0001-7095-4924
Observed ORCID: 0000-0001-7095-4924
OpenAlex ID: A5025763305
Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study
2020 · Camila Peña, Eloisa Riva, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 29
Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study
2022 · Eloísa Riva, Patricio José Duarte, et al. · JCO Global Oncology · 25
Significant differences in access to tests and treatments for multiple myeloma between public and private systems in Latin America. Results of a Latin American survey. GELAMM (Grupo de Estudio Latino Americano de Mieloma Múltiple)
2020 · Eloísa Riva, N. Schütz, et al. · Annals of Hematology · 22
Epidemiology and Risk Factors for the Development of Infectious Complications in Newly Diagnosed Multiple Myeloma: A Multicenter Prospective Cohort Study in Latin America
2022 · Virginia Bove, Eloísa Riva, et al. · JCO Global Oncology · 13
Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients' Evidence From Latin America
2023 · Humberto Martínez-Cordero, Camila Peña, et al. · JCO Global Oncology · 12
PDF
Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma
2020 · Virginia Bove, David Garrido, et al. · Hematology Transfusion and Cell Therapy · 12
PDF
Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group
2023 · Camila Peña, Eloísa Riva, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 8
Consenso del Grupo Latinoamericano de estudio de Mieloma Múltiple (MM) GELAMM para el manejo del MM en estado de Pandemia SARS CoV-2 / COVID 19: Recomendaciones Basadas en Consenso de Expertos
2020 · Humberto Martinez-Codero, Lina María Martínez, et al. · Revista Colombiana de Cancerología · 4
PDF
Efectividad del tratamiento con bortezomib en pacientes con mieloma múltiple en el Hospital de Clínicas en el período 2009-2016. Montevideo, Uruguay
2018 · Sabrina Ranero, Virginia Bove, et al. · Revista Médica del Uruguay · 4
PDF
Epidemiology and risk factors for the development of infectious complications in newly diagnosed multiple myeloma: a multicenter prospective cohort study in Uruguay
2023 · Eloísa Riva, David Garrido, et al. · Hematology Transfusion and Cell Therapy · 3
From guidelines to real world: results from the National Multiple Myeloma Registry in Uruguay on 222 newly diagnosed multiple myeloma patients from 2012 to 2015
2019 · E. Riva, V. Bove, et al. · Current Medical Research and Opinion · 3
Significant Differences in Test Availability and Access to Novel Drugs for Multiple Myeloma between Public and Private Hospitals in Latin America. Grupo De Estudio Latinoamericano De Mieloma Multiple (GELAMM)
2018 · Eloisa Riva, Natalia Paola Schutz, et al. · Blood · 3
Diffuse large B cell lymphoma presenting with acute liver failure: a case report
2015 · Sofia Grille, Matilde Boada, et al. · Case Reports in Clinical Pathology · 3
PDF
Myelodysplastic syndrome with dual germline RUNX1 and DDX41 variants: a rare genetic predisposition case
2025 · Virginia Bove, Maria Noel Spangenberg, et al. · Familial Cancer · 2
Comparative survival analysis using the International Stratification Score (ISS) in newly-diagnosed multiple myeloma in the Uruguayan population
2021 · David Israel Garrido, Virginia Bove, et al. · Medicine and Pharmacy Reports · 2
PDF
Unequal Outcomes in Transplant Eligible Patients with Multiple Myeloma in Latin America: Differences between Public and Private Centers
2019 · Camila Peña, Natalia Paola Schutz, et al. · Blood · 2
Real World Outcomes in Latin-American Patients with Multiple Myeloma Under 40 Years Old
2019 · Humberto Martínez-Cordero, Camila Peña, et al. · Blood · 2
Survival Analysis of Newly Diagnosed Multiple Myeloma Patients after Frontline Autologous Stem Cell Transplantation in a Real-Life Setting
2023 · David Garrido, Virginia Bove, et al. · Acta Medica (Hradec Kralove Czech Republic) · 1
PDF
Multiple Myeloma Patients Aged 40 Years and Younger Have the Same Prognosis As Older Patients in an Analysis of Real-World Evidence from Latin America: A Study of 1,316 Patients from the Gelamm Latin American Multiple Myeloma Studygroup
2022 · Humberto Martinez-Cordero, Camila Peña, et al. · Blood · 1
Real-World Data on Multiple Myeloma: A Prospective National Registry in Uruguay
2015 · Eloisa Riva, Virginia Bove, et al. · Blood · 1
First report of real-word outcomes of chronic myeloid leukemia in Uruguay in tyrosine kinase inhibitor era
2025 · Virginia Bove, Mariana Lorenzo, et al. · Blood
PDF
Characteristics and Outcomes of Multiple Myeloma Patients with Post-Transplant Relapse: A Latin American Real-World Cohort Study
2025 · Camila Peña, Patricio Duarte, et al. · Clinical Lymphoma Myeloma & Leukemia
P-359 Survival of Patients With Multiple Myeloma Treated With Bortezomib-Based Triplets and Autologous Hematopoietic Stem Cell Transplant As Frontline in Latin America
2024 · Camila Peña, Virginia Bove, et al. · Clinical Lymphoma Myeloma & Leukemia
Survival of Patients with Multiple Myeloma Treated with Bortezomib-Based Triplets and Autologous Hematopoietic Stem Cell Transplant As First Line in Latin America
2023 · Camila Peña, Virginia Bove, et al. · Blood
PDF
P-151: Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group
2022 · Camila Peña, Natalia Schutz, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 34
Citation count: 152
H-index: 7
I10-index: 6
Year
Topic
Type